In the context of combined chemical peeling and injectable treatments, careful consideration of the post-peel inflammatory phase is essential. Injectable procedures are not recommended until erythema has fully resolved, as persistent inflammation reflects ongoing dermal remodeling and barrier disruption. This is particularly critical in patients with Fitzpatrick skin types III–V, who exhibit a higher propensity for prolonged erythema and post-inflammatory hyperpigmentation, necessitating more conservative treatment intervals.
When cross-linked hyaluronic acid is delivered into the superficial dermis or papillary dermal plane, it may become susceptible to secondary degradation following trichloroacetic acid (TCA) application. Although TCA does not directly dissolve hyaluronic acid, it induces a controlled inflammatory cascade characterized by increased matrix metalloproteinase activity, reactive oxygen species generation, and potential upregulation of endogenous hyaluronidases. These processes may accelerate the breakdown of superficially placed HA, particularly when dermal injury overlaps with the filler plane.
Clinically, this interaction becomes more relevant at TCA concentrations of 25–35%, where penetration into the papillary and upper reticular dermis is achieved, leading to more pronounced inflammation and tissue remodeling. In such cases, a reduction in filler longevity may be observed, not due to direct chemical degradation, but secondary to biologically mediated resorption.
The duration of post-TCA erythema is directly correlated with peel depth and concentration. While erythema typically resolves within 4–8 weeks, it may persist beyond 12 weeks in certain patients. Complete epidermal restoration and stabilization of the dermal microenvironment are prerequisites before considering superficial injection procedures. Performing injections prior to full barrier recovery may increase the risk of unpredictable filler behavior, accelerated degradation, and pigmentary complications.
Therefore, when combining TCA peeling with superficial scar filler treatments, a staged approach is recommended. TCA should be performed first, followed by close clinical monitoring of the healing process. In my clinical practice, I adopt a conservative interval of at least 3 months after TCA application before performing superficial dermal filler injections. This strategy aims to ensure complete resolution of inflammation, restoration of epidermal integrity, and optimization of filler longevity and safety.